Academic Journal
Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19
| العنوان: | Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19 |
|---|---|
| المؤلفون: | Çaǧlayan, Şengül, Sönmez, Hafize Emine, Otar Yener, Gülçin, Baǧlan, Esra, Öztürk, Kübra, Ulu, Kadir, Guliyeva, Vafa, Demirkol, Demet, Çakan, Mustafa, Özdel, Semanur, Bukulmez, Hulya, Aktay Ayaz, Nuray, Sözeri, Betül |
| المصدر: | Frontiers in Pediatrics ; volume 10 ; ISSN 2296-2360 |
| بيانات النشر: | Frontiers Media SA |
| سنة النشر: | 2022 |
| المجموعة: | Frontiers (Publisher - via CrossRef) |
| الوصف: | Objective The study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in children (MIS-C). Methods This is a cross-sectional retrospective study consisting of pediatric patients diagnosed with MIS-C who were treated with anakinra. Results Among the 378 patients diagnosed with MIS-C, 82 patients (21.6%) who were treated with anakinra were included in the study. The median age of patients was 115 (6-214) months. The median duration of hospitalization was 15 (6-42) days. Sixty patients (73.1%) were admitted to the pediatric intensive care unit. Patients were treated with a median dose of 2.7 mg/kg/day anakinra concomitant with IVIG and steroids. Intravenous anakinra was applied to 12 patients while 70 patients received it subcutaneously. Twenty-eight patients required high dose (4–10 mg/kg/day) anakinra. The median day of anakinra initiation was 2 (1-14) days and the median duration of anakinra use was 7 (1-41) days. No injection site reactions were observed while elevated transaminase levels were detected in 13 patients. Seventy-three patients (89.1%) were discharged without any sequela or morbidity. Seven patients (1.8%) died. Abnormal echocardiographic findings continued in two patients (2.4%) (coronary artery dilatation in one, low ejection fraction in one) at discharge and became normal on the 2 nd month. Conclusion Based on the results of the study, anakinra was associated with clinical improvements and was safe for most patients with refractory MIS-C. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| DOI: | 10.3389/fped.2022.942455 |
| DOI: | 10.3389/fped.2022.942455/full |
| الاتاحة: | http://dx.doi.org/10.3389/fped.2022.942455 https://www.frontiersin.org/articles/10.3389/fped.2022.942455/full |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.8D797A10 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fped.2022.942455 |
|---|